Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chorionic gonadotropin + menotropins
- Development stage
- Unknown
- Lead developer
- Ferring Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
chorionic gonadotropin + menotropins is a combination hormonal therapy used primarily for the treatment of male infertility and hypogonadism, specifically congenital hypogonadotropic hypogonadism (CHH). Human chorionic gonadotropin (hCG) serves as an analog for luteinizing hormone (LH), binding to the Luteinizing hormone/choriogonadotropin receptor (LHCGR) on Leydig cells to stimulate the endogenous production of testosterone. Menotropins (human menopausal gonadotropin or hMG) is a purified extract containing both follicle-stimulating hormone (FSH) and LH activity; the FSH component binds to the Follicle stimulating hormone receptor (FSHR) on Sertoli cells to initiate and maintain spermatogenesis. This combination therapy is essential for patients who lack sufficient endogenous gonadotropin secretion to support normal reproductive and sexual function.
- Other names
- hCG + hMGhuman chorionic gonadotropin + human menopausal gonadotropin
02
Targets
FSHR (Follicle-stimulating hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on chorionic gonadotropin + menotropins.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chorionic gonadotropin + menotropins.